Last Sunday's report called it: the five-week slide had paused, but the question was whether that was stabilisation or a setup for the next leg lower. This week ORCL answered it, falling another 9.6% to close at $127.94 — erasing the brief respite and bringing the cumulative drawdown from the June 9 pre-earnings close to roughly 38%.
The peer gap makes the move harder to explain as sector-wide pressure. RBRK gained 1.2% on the week. ESTC added nearly 5%. CDNS rose 1.5%. Even MSFT only slipped 1%. Oracle fell nearly 10%. As was the case in prior weeks, the software sector is not the problem — Oracle is being re-rated on its own terms, and that process appears unfinished.
Options traders are sending a notably different signal from recent weeks, and that divergence is the most interesting thing in the data right now. The put/call ratio has dropped to 0.83, more than two standard deviations below its 20-day average of 0.95 — making this week's reading one of the most call-heavy configurations of the past year. That is a sharp reversal from the defensive posture in place through late June and early July, when the PCR was running above 1.0. With the stock still falling hard, elevated call positioning against a deteriorating price trend is an unusual combination. It could reflect hedging strategies being unwound, or opportunistic dip-buying in calls at compressed levels — but the contrast between the options lean and the tape is stark.
Short interest tells a far less dramatic story. At 1.37% of the free float, short positioning is low in absolute terms and has barely moved — up roughly 4% on the week after ticking down 1.3% on Tuesday. The borrow market remains extraordinarily loose, with availability at the practical ceiling of 9,999%, unchanged on the week, meaning there is no pressure whatsoever on lenders. Cost to borrow edged up 27% on the week but at 0.42% remains trivially cheap. The July 8 note flagged this disconnect — shorts retreating even as the stock fell — and it remains the defining feature of the lending setup. This is not a short-driven decline. Sellers have little friction and no urgency to cover.
The Street remains broadly constructive despite the carnage, though analyst data here is now 34 days old relative to today, so treat it as directional rather than current. Following the June 10 earnings reaction, most coverage was maintained at bullish ratings with targets cut. The consensus price target ran near $253 at that point — roughly double the current price — reflecting the scale of the derating rather than any fresh analyst conviction. Factor scores are more timely: EPS momentum over 90 days ranks in the 92nd percentile, and the analyst recommendation differential scores in the 94th percentile. Those are strong readings. They describe a company the Street still likes. They do not explain why the stock is at $127.94.
The institutional picture is dominated by one name. Larry Ellison holds 40% of shares outstanding, a concentration that makes traditional float-driven analysis less meaningful than usual. Among active managers, BlackRock and Capital Research both added modestly in the most recent period. Executive Vice Chairman Jeff Henley sold approximately $61 million of stock on June 24 — at prices around $156-$165, well above current levels. The 90-day insider net is technically positive in share terms but that reflects the aggregation of small purchases against Henley's large disposal. The insider story is not bullish.
The next earnings event is September 4. The most recent print on June 10 produced a 10.5% one-day drop and an 10.8% five-day loss — the largest single-session reaction in recent history. With the stock now 38% below its pre-earnings level and the PCR at an unusual two-standard-deviation low, what traders watch into September is whether the call-heavy options positioning reflects genuine recovery conviction or simply the cost of downside protection having become too expensive to sustain.
See the live data behind this article on ORTEX.
Open ORCL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
